Get the Stockscreener App
3.235
7.81%
-0.285
Prokidney Corp stock is traded at $3.235, with a volume of 4.11M.
It is down -7.81% in the last 24 hours and up +366.03% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$3.52
Open:
$3.56
24h Volume:
4.11M
Relative Volume:
0.35
Market Cap:
$691.11M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-5.6754
EPS:
-0.57
Net Cash Flow:
$-124.27M
1W Performance:
-28.52%
1M Performance:
+366.03%
6M Performance:
+95.48%
1Y Performance:
+48.17%
1-Day Range:
$3.16
$3.56
1-Week Range:
$3.15
$4.95
52-Week Range:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
3.2435 | 691.11M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.67 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.95 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.50 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
565.25 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.61 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
What drives ProKidney Corp. stock priceSuperior capital gains - Jammu Links News
What analysts say about ProKidney Corp. stockFree Predictions - Jammu Links News
ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy - MSN
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Best Momentum Stocks to Buy for July 17th - TradingView
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN
ProKidney gains pivotal therapy advancement step with FDA - Winston-Salem Journal
ProKidney completes Delaware domestication and restructures corporate agreements - Investing.com
Citi Maintains ProKidney(PROK.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Will ProKidney’s Recent Surge Last? - StocksToTrade
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
ProKidney’s Strategic FDA Alignment and Promising Clinical Data Drive Buy Rating - TipRanks
ProKidney’s Hold Rating: Balancing FDA Alignment and Extended Approval Timeline - TipRanks
ProKidney price target raised to $7 from $6 at Guggenheim - MSN
ProKidney’s Dramatic Shares Tumble - timothysykes.com
Is ProKidney’s Slide a Buy Signal? - StocksToTrade
ProKidney Shares Plummet Amid Downgrades - timothysykes.com
UBS Initiates ProKidney(PROK.US) With Buy Rating, Announces Target Price $8 - 富途牛牛
ProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug Trial - MarketScreener
ProKidney Stock Skyrockets: What Does This Mean? - StocksToTrade
ProKidney, FDA align on accelerated approval pathway for Rilparencel - MSN
UBS Adjusts ProKidney Price Target to $8 From $4, Maintains Buy Rating - MarketScreener
ProKidney stock soars after FDA confirms accelerated approval pathway - Investing.com
Sector Update: Health Care - MarketScreener
ProKidney Soars 29.27% on FDA Milestone for CKD Therapy - AInvest
ProKidney Says FDA Confirms Accelerated Approval Pathway for Rilparencel - MarketScreener
Prokidney announces alignment with the FDA on the accelerated approval pathway for rilparencel - MarketScreener
ProKidney announces alignment with the FDA on the accelerated approval pathway for rilparencel - grafa.com
ProKidney Secures FDA Alignment for Rilparencel Approval - TipRanks
Why Did ProKidney Stock Plunge 5.15% Despite 169% YTD Surge? - AInvest
ProKidney stock price target raised to $8 from $4 at UBS on promising data By Investing.com - Investing.com South Africa
ProKidney stock price target raised to $8 from $4 at UBS on promising data - Investing.com India
ProKidney stock falls after FDA alignment on rilparencel approval pathway - Investing.com
ProKidney announces alignment with FDA on rilparencel accelerated approval path - TipRanks
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel - GlobeNewswire
ProKidney price target raised to $8 from $4 at UBS - TipRanks
ProKidney Enters New $200M Sale Agreement with Jefferies - TipRanks
ProKidney Plummets 26%—Is This the End of a Biotech Rally? - AInvest
ProKidney Faces Turbulence as Stock Plunges Amid Downgrades - StocksToTrade
ProKidney: Guggenheim maintains a 'Buy' Rating, The Target Price is $7 - AInvest
ProKidney's Innovative CKD Treatment Sparks Biotech InterestNews and Statistics - IndexBox
ProKidney stock price target raised to $7 from $6 at Guggenheim - Investing.com Australia
ProKidney stock price target raised to $7 from $6 at Guggenheim By Investing.com - Investing.com South Africa
ProKidney Just Set A New 52-Week High. Should You Buy, Sell, Or Hold PROK Stock Here? - Barchart.com
Promising clinical trial results give ProKidney share price major boost - Winston-Salem Journal
ProKidney spikes after mid-stage trial data for lead asset - MSN
The Globe’s stars and dogs for the week - The Globe and Mail
High-Potential Biotech Penny Stocks in 2025: ProKidney and Design Therapeutics Lead the Way - AInvest
ProKidney’s Investigation: A Game Changer? - timothysykes.com
ProKidney Stock (PROK): Is the Hype Justified? - Value The Markets
ProKidney Stock Soars 11.75% on Positive Phase 2 Study Results - AInvest
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):